STRYKER CORP

SYK

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

RTW Investments OrbiMed Advisors Deerfield Management

Position Trend

Feb 13, 2026

$3.0M

1 fund

Feb 17, 2026

$201.6M

3 funds

+6531% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

RTW InvestmentsNEWFeb 17, 2026

Shares: 245,000Value: $86.1M

**Signal Note: RTW Investments enters SYK** Wong's new $86.1M position in Stryker suggests conviction in the orthopedic/surgical device franchise, likely driven by upcoming catalyst visibility in spine or robotics segments where SYK has competitive positioning. This represents a notable allocation for RTW's data-driven approach and suggests quantitative models are flagging favorable risk-reward, though the specific catalyst (product launch, M&A, procedure volume recovery) requires clarification. Monitor for related biotech/medtech plays in Wong's portfolio that may indicate thematic conviction.

OrbiMed AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IRON4 funds ISRG4 funds CELC4 funds NBIX3 funds ARGX3 funds PRAX3 funds ALNY3 funds AXSM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: OrbiMed Initiates $114M Stryker Position OrbiMed's substantial new position in Stryker signals confidence in the orthopedic/surgical device leader's near-term execution and M&A potential. The timing aligns with Stryker's competitive positioning in high-growth segments (robotic-assisted surgery, spine, trauma) and suggests the mega-cap healthcare fund sees undervalued upside relative to peers. No specific catalyst or product launch is publicly disclosed, but the large entry size from a top-tier healthcare investor typically precedes institutional accumulation cycles.